| Name | Title | Contact Details |
|---|
Apervita is the trusted healthcare collaboration platform for quality measurement, clinical intelligence, value optimization and interoperability. We empower payers and providers and other stakeholders to more efficiently and effectively measure clinical and financial performance, improve clinical quality and administer and run analytics on value-based contracts. By providing an independent, secure, trusted platform to perform shared analyses, Apervita uniquely allows stakeholders to gain mutual, continuous clinical and financial insights and integrate those insights in various systems and workflows simultaneously and at scale. Serving more than one in three hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 10 billion value-based computations and insights for our clients every year. Serving more than one in five hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 1 billion value-based computations and insights for our clients every year. Founded in 2012, the company maintains office locations in Chicago and Boston.
Community Health Center of the North Country is a healthcare provider with locations in St. Lawrence, Franklin, and Jefferson counties in Northern New York. They offer comprehensive primary, pediatric, behavioral, dental, optometry, and preventative ca...
IcareUSA Foundation is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Midmark Corporation makes medical, dental, and veterinary products and provides related services. It was founded in 1915 as The Cummings Machine Company.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.